Tremendous disparities are known to exist in cardiovascular disease and its related outcomes. Much of this can be traced to poorly controlled hypertension and its attendant, pressure-related consequences, especially target-organ cardiac damage. The latter, which occurs prematurely and disproportionately in African- Americans, reduces both quality and quantity of life. The risk of target-organ cardiac damage is particularly high among inner-city African-Americans with hypertension, particularly those who utilize the emergency department for chronic blood pressure management. Like cardiovascular disease, vitamin D deficiency disproportionately affects African-Americans. Vitamin D is thought to be an important modifier of cardiovascular disparities through its direct (and, via parathyroid hormone, indirect) myocardial (hypertrophy, fibrosis) and vascular (increased resistance, loss of compliance) effects. Vitamin D repletion in those who are deficient has been postulated as mechanism to reduce the cardiovascular disease burden experienced by African- Americans, especially if initiated early before irreversible damage has occurred, but this has yet to be tested in a prospective clinical trial. Accordingly, this proposal was designed to investigate the relationship between vitamin D and subclinical target-organ cardiac damage (as identified on cardiac magnetic resonance imaging) in a cohort of African-American, vitamin D deficient hypertensive patients without prior history of heart disease. Specifically, we seek to ascertain the effect of adjunct vitamin D therapy on left ventricular hypertrophy (primary aim), myocardial fibrosis and central vascular function (secondary aims) at one-year using a placebo controlled, randomized design. Antihypertensive treatment in both study arms will be standardized and our focus will be recruitment of patients who present to our safety-net institution with poorly controlled blood pressure - a high-risk, high-reward subset who would stand to benefit tremendously from identification of an inexpensive intervention, which could effectively reduce the adverse impact of hypertension.

Public Health Relevance

African-Americans die younger and more often from hypertension and hypertensive heart disease than other races. Regression of left ventricular hypertrophy, a cardinal manifestation of elevated blood pressure, which disproportionately affects African-Americans, can reduce adverse events and, accordingly, has become a focal point of secondary prevention. Vitamin D deficiency may be an important contributor to racial differences in hypertensive heart disease but whether adjunct vitamin D therapy provides benefit is unknown.

National Institute of Health (NIH)
National Institute on Minority Health and Health Disparities (NIMHD)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZMD1-MLS (01))
Program Officer
Rajapakse, Nishadi
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wayne State University
Emergency Medicine
Schools of Medicine
United States
Zip Code
Brody, Aaron M; Flack, John M; Ference, Brian A et al. (2014) Utility of Framingham risk score in urban emergency department patients with asymptomatic hypertension. Crit Pathw Cardiol 13:114-6
Levy, Phillip D; Laribi, Said; Mebazaa, Alexandre (2014) Vasodilators in Acute Heart Failure: Review of the Latest Studies. Curr Emerg Hosp Med Rep 2:126-132
Mahn, James J; Dubey, Elizabeth; Brody, Aaron et al. (2014) Test characteristics of electrocardiography for detection of left ventricular hypertrophy in asymptomatic emergency department patients with hypertension. Acad Emerg Med 21:996-1002
Levy, Phillip D; Bellou, Abdel (2013) Acute Heart Failure Treatment. Curr Emerg Hosp Med Rep 1: